Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman

Sanshiro Nakao; Sho Tanaka; Kazuki Abe; Tomomi Komiyama; Yoshiya Sugiura; Chiaki Nakaseko; Naomi Shimizu

doi:10.2169/internalmedicine.2701-23

Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman

Intern Med. 2023 Nov 20. doi: 10.2169/internalmedicine.2701-23. Online ahead of print.

Authors

Sanshiro Nakao¹, Sho Tanaka², Kazuki Abe², Tomomi Komiyama², Yoshiya Sugiura³, Chiaki Nakaseko⁴, Naomi Shimizu¹

Affiliations

¹ Department of Hematology, Toho University Sakura Medical Center, Japan.
² Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan.
³ Department of Surgical Pathology, Toho University Sakura Medical Center, Japan.
⁴ Department of Hematology, International University of Health and Welfare School of Medicine, Japan.

PMID: 37981304
DOI: 10.2169/internalmedicine.2701-23

Abstract

In recent years, lesbian, gay, bisexual, and transgender (LGBT) populations have been gaining acceptance in society. However, very few cases of malignancy in the LGBT population have been reported thus far. We herein report a transgender woman receiving estrogen supplementation who developed primary mediastinal large B-cell lymphoma (PMBCL) and was treated with dose-adjusted EPOCH-rituximab (DA-EPOCH-R) therapy. The patient achieved complete remission after the sixth course of DA-EPOCH-R therapy. To help this LGBT patient continue receiving chemotherapy smoothly on admission, adjusting the hospital environment, such as the allocation of rooms, was essential.

Keywords: Dose-adjusted etoposide; Primary mediastinal B-cell lymphoma; Transgender woman; cyclophosphamide with vincristine and prednisone plus rituximab therapy; doxorubicin; estrogen.